Progress of quantitative measurement of bone using 99mTc-methylene diphosphonate in osteoporosis _Journal of Biomedical Engineering

Authors：

YAO Yutang ,  OU Xiaohong

Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;

Corresponding author：

OU Xiaohong, Email: xiaohong_ou@163.com

Keywords：

osteoporosis; bone turnover; radionuclide bone quantitative measurement; ^99mTc-methylene diphosphonate; standardized uptake value

DOI：

10.7507/1001-5515.201702007

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

As the incidence of osteoporosis (OP) is increasing year by year, high morbidity and mortality caused by osteoporotic fractures have become major problems of health in China and over the world. Quantitative measurement of bone using ^99mTc-methylene diphosphonate (^99mTc-MDP) provides global or local information of skeletal metabolism or transformation. In this paper, we make a brief review on the quantitative measurement of bone using ^99mTc-MDP and expect to provide guidance for clinical diagnosis and treatment.

Citation： YAO Yutang, OU Xiaohong. Progress of quantitative measurement of bone using ^99mTc-methylene diphosphonate in osteoporosis . Journal of Biomedical Engineering, 2017, 34(5): 812-816. doi: 10.7507/1001-5515.201702007 Copy

1.	Wright N C, Looker A C, Saag K G, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. Journal of Bone and Mineral Research, 2014, 29(11): 2520-2526.
2.	Si L, Winzenberg T M, Jiang Q, et al. Projection of osteoporosis-related fractures and costs in China: 2010-2050. Osteoporos Int, 2015, 26(7): 1929-1937.
3.	Osaki M. Hip fracture—epidemiology, management and liaison service. Rehabilitation for the hip fracture. Clin C, 2015, 25(4): 577-584.
4.	Blake G M, Siddique M, Frost M L, et al. Imaging of site specific bone turnover in osteoporosis using positron emission tomography. Curr Osteoporos Rep, 2014, 12(4): 475-485.
5.	Camacho P M, Petak S M, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016 Executive Summary. Endocr Pract, 2016, 22(9): 1111-1118.
6.	Eriksen E F, Keaveny T M, Gallagher E R. Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone, 2014, 67: 246-256.
7.	Croucher P I, Parker B S, Corcoran N, et al. Bone turnover markers and prostate Cancer: not just a measure of bone disease? Eur Urol, 2015, 68(1): 51-52.
8.	Redmond J, Fulford A J, Jarjou L, et al. Diurnal rhythms of bone turnover markers in three ethnic groups. J Clin Endocrinol Metab, 2016, 101(8): 3222-3230.
9.	Grávalos C, Rodríguez C, Sabino A, et al. SEOM clinical guideline for bone metastases from solid tumours (2016) Clin Transl Oncol, 2016, 18(12): 1243-1253.
10.	Ritt P, Vija H, Hornegger J, et al. Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging, 2011, 38(Suppl 1): S69-S77.
11.	Fogelman I, Bessent R G, Turner J G, et al. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med, 1978, 19(3): 270-275.
12.	Sullivan D C, Obuchowski N A, Kessler L G, et al. Metrology standards for quantitative imaging biomarkers. Radiology, 2015, 277(3): 813-825.
13.	Cachovan M, Vija A H, Hornegger J A. Quantification of <sup>99m</sup>Tc-DPD concentration in the lumbar spine with SPECT/CT. EJNMMI Res, 2013, 3(1): 45-52.
14.	Beck M, Sanders J C, Ritt P, et al. Longitudinal analysis of bone metabolism using SPECT/CT and <sup>99m</sup>Tc-diphosphono-propanedicarboxylic acid: comparison of visual and quantitative analysis. EJNMMI Res, 2016, 6(1): 60-68.
15.	Suh M S, Lee W W, Kim Y K, et al. Maximum standardized uptake value of (99m) Tc hydroxymethylene diphosphonate SPECT/CT for the evaluation of temporomandibular joint disorder. Radiology, 2016, 280(3): 890-896.
16.	Kaneta T, Ogawa M, Daisaki H, et al. SUV measurement of normal vertebrae using SPECT/CT with Tc-99m methylene diphos-phonate. Am J Nucl Med Mol Imaging, 2016, 6(5): 262-268.
17.	D’addabbo A, Rubini G, Mele M, et al. A new method for assessing 99Tcm-MDP bone uptake from a bone scan image: quantitative measurement of radioactivity in global skeletal regions of interest. Nucl Med Commun, 1992, 13(1): 55-60.
18.	Brenner W, Bohuslavizki K H, Sieweke N, et al. Quantification of diphosphonate uptake based on conventional bone scanning. Eur J Nucl Med, 1997, 24(10): 1284-1290.
19.	Blake G M, Moore A E, Fogelman I. Quantitative studies of bone using <sup>99m</sup>Tc-methylene diphosphonate skeletal plasma clearance. Semin Nucl Med, 2009, 39(6): 369-379.
20.	Park-Holohan S J. Blake G M, Fogelman I. Quantitative studies of bone using 18F-fluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole-blood kinetics. Nucl Med Commun, 2001, 22(9): 1037-1044.
21.	Moore A E, Blake G M, Fogelman I. Quantitative measurements of bone remodeling using <sup>99m</sup>Tc-methylene diphosphonate bone scans and blood sampling. J Nucl Med, 2008, 49(3): 375-382.
22.	Shibutani T, Onoguchi M, Noguchi A, et al. Reproducibility between brain uptake ratio using anatomic standardization and Patlak-Plot methods. J Nucl Med Technol, 2015, 43(4): 261-266.
23.	Moore A E, Blake G M, Taylor K A, et al. Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis. Eur J Nucl Med Mol Imaging, 2012, 39(2): 326-336.
24.	Kuwert T. Skeletal SPECT/CT: a review. Clinical and Translational Imaging, 2014, 2(6): 505-517.
25.	Treves S T, Falone A E, Fahey F H. Pediatric nuclear medicine and radiation dose. Semin Nucl Med, 2014, 44(3): 202-209.
26.	Lewiecki E M. Imaging technologies for assessment of skeletal health in men. Curr Osteoporos Rep, 2013, 11(1): 1-10.
27.	Livieratos L. Technical pitfalls and limitations of SPECT/CT. Semin Nucl Med, 2015, 45(6): 530-540.
28.	Hutton B F, Ben-Haim S. What are the necessary corrections for dynamic cardiac SPECT?. J Nucl Cardiol, 2016: 1-3.

1. Wright N C, Looker A C, Saag K G, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. Journal of Bone and Mineral Research, 2014, 29(11): 2520-2526.
2. Si L, Winzenberg T M, Jiang Q, et al. Projection of osteoporosis-related fractures and costs in China: 2010-2050. Osteoporos Int, 2015, 26(7): 1929-1937.
3. Osaki M. Hip fracture—epidemiology, management and liaison service. Rehabilitation for the hip fracture. Clin C, 2015, 25(4): 577-584.
4. Blake G M, Siddique M, Frost M L, et al. Imaging of site specific bone turnover in osteoporosis using positron emission tomography. Curr Osteoporos Rep, 2014, 12(4): 475-485.
5. Camacho P M, Petak S M, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016 Executive Summary. Endocr Pract, 2016, 22(9): 1111-1118.
6. Eriksen E F, Keaveny T M, Gallagher E R. Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone, 2014, 67: 246-256.
7. Croucher P I, Parker B S, Corcoran N, et al. Bone turnover markers and prostate Cancer: not just a measure of bone disease? Eur Urol, 2015, 68(1): 51-52.
8. Redmond J, Fulford A J, Jarjou L, et al. Diurnal rhythms of bone turnover markers in three ethnic groups. J Clin Endocrinol Metab, 2016, 101(8): 3222-3230.
9. Grávalos C, Rodríguez C, Sabino A, et al. SEOM clinical guideline for bone metastases from solid tumours (2016) Clin Transl Oncol, 2016, 18(12): 1243-1253.
10. Ritt P, Vija H, Hornegger J, et al. Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging, 2011, 38(Suppl 1): S69-S77.
11. Fogelman I, Bessent R G, Turner J G, et al. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med, 1978, 19(3): 270-275.
12. Sullivan D C, Obuchowski N A, Kessler L G, et al. Metrology standards for quantitative imaging biomarkers. Radiology, 2015, 277(3): 813-825.
13. Cachovan M, Vija A H, Hornegger J A. Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CT. EJNMMI Res, 2013, 3(1): 45-52.
14. Beck M, Sanders J C, Ritt P, et al. Longitudinal analysis of bone metabolism using SPECT/CT and 99mTc-diphosphono-propanedicarboxylic acid: comparison of visual and quantitative analysis. EJNMMI Res, 2016, 6(1): 60-68.
15. Suh M S, Lee W W, Kim Y K, et al. Maximum standardized uptake value of (99m) Tc hydroxymethylene diphosphonate SPECT/CT for the evaluation of temporomandibular joint disorder. Radiology, 2016, 280(3): 890-896.
16. Kaneta T, Ogawa M, Daisaki H, et al. SUV measurement of normal vertebrae using SPECT/CT with Tc-99m methylene diphos-phonate. Am J Nucl Med Mol Imaging, 2016, 6(5): 262-268.
17. D’addabbo A, Rubini G, Mele M, et al. A new method for assessing 99Tcm-MDP bone uptake from a bone scan image: quantitative measurement of radioactivity in global skeletal regions of interest. Nucl Med Commun, 1992, 13(1): 55-60.
18. Brenner W, Bohuslavizki K H, Sieweke N, et al. Quantification of diphosphonate uptake based on conventional bone scanning. Eur J Nucl Med, 1997, 24(10): 1284-1290.
19. Blake G M, Moore A E, Fogelman I. Quantitative studies of bone using 99mTc-methylene diphosphonate skeletal plasma clearance. Semin Nucl Med, 2009, 39(6): 369-379.
20. Park-Holohan S J. Blake G M, Fogelman I. Quantitative studies of bone using 18F-fluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole-blood kinetics. Nucl Med Commun, 2001, 22(9): 1037-1044.
21. Moore A E, Blake G M, Fogelman I. Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling. J Nucl Med, 2008, 49(3): 375-382.
22. Shibutani T, Onoguchi M, Noguchi A, et al. Reproducibility between brain uptake ratio using anatomic standardization and Patlak-Plot methods. J Nucl Med Technol, 2015, 43(4): 261-266.
23. Moore A E, Blake G M, Taylor K A, et al. Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis. Eur J Nucl Med Mol Imaging, 2012, 39(2): 326-336.
24. Kuwert T. Skeletal SPECT/CT: a review. Clinical and Translational Imaging, 2014, 2(6): 505-517.
25. Treves S T, Falone A E, Fahey F H. Pediatric nuclear medicine and radiation dose. Semin Nucl Med, 2014, 44(3): 202-209.
26. Lewiecki E M. Imaging technologies for assessment of skeletal health in men. Curr Osteoporos Rep, 2013, 11(1): 1-10.
27. Livieratos L. Technical pitfalls and limitations of SPECT/CT. Semin Nucl Med, 2015, 45(6): 530-540.
28. Hutton B F, Ben-Haim S. What are the necessary corrections for dynamic cardiac SPECT?. J Nucl Cardiol, 2016: 1-3.

Previous Article
The application of silicon nanowires field-effect transistor biosensor in medicine

Journal of Biomedical Engineering

Progress of quantitative measurement of bone using ^99mTc-methylene diphosphonate in osteoporosis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content